Results Peroral d-allulose suppresses food intake without aversion Peroral (p.o.) administration of d-allulose (Allu) at 1 and 3 g kg 1 , but not 0.3 g kg 1 , into the stomach using a stainless feeding needle decreased cumulative food intake for 0.5, 1, 2, 3, and 6 h after injection in C57BL/6J mice fasted overnight (16 h) (Fig
Long-term chronic mold exposure has been associated with persistent immune dysregulation, hepatic and renal stress, and degenerative inflammatory patterns
& le Roux, C
In general, oral therapies are associated with improved convenience acceptance and compliance by patients, particularly when taking additional medications, as is often the case in the management of diabetes
Key Features Specifically formulated as a potent GIP/GLP-1/GCG receptor agonist to target the primary pathways of glucose control and lipid metabolism